keyword
MENU ▼
Read by QxMD icon Read
search

Central retinal vein

keyword
https://www.readbyqxmd.com/read/28931297/-intracranial-pressure-evaluation-by-ophthalmologist
#1
J Čmelo, R Illéš, J Šteňo
The value of ICT is important in diagnosis of the diseases of the eye and orbit Methods for direct measurement of intracranial pressure (ICT) are exact, but they are invasive and there is some risk of infection and damage of the tissue. Currently there are 2 valid indirect methods of mesurement of IKT. Digital Ophthalmodynamometry (D-ODM) and Transcranial Doppler ultrasonography (TDU). D-ODM is a non-invasive method for measuring of the Pulsating Venous Pressure (VPT). We can measure VPT by the pulse phenomena...
2017: Ceská a Slovenská Oftalmologie
https://www.readbyqxmd.com/read/28931295/-two-year-follow-up-results-of-patients-with-macular-oedema-due-to-retinal-vein-occlusion-treated-with-ranibizumab
#2
Z Hladíková, E Klofáčová, B Kalvodová
PURPOSE: To evaluate 2-year follow-up results of patients with macular oedema (ME) caused by central (CRVO) and branch (BRVO) retinal vein occlusion treated with intravitreal ranibizumab at the Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. METHODS: Retrospective study. RESULTS: The 2-year follow-up was completed by 18 patients with ME caused by CRVO and 16 patients with ME caused by BRVO...
2017: Ceská a Slovenská Oftalmologie
https://www.readbyqxmd.com/read/28924438/central-retinal-vein-occlusion-in-2-patients-using-antipsychotic-drugs
#3
Koichiro Taki, Teruyo Kida, Masanori Fukumoto, Takaki Sato, Hidehiro Oku, Tsunehiko Ikeda
PURPOSE: To report our findings in 2 patients who developed a central retinal vein occlusion (CRVO) and were chronic users of antipsychotic medications. CASE PRESENTATION: Case 1 was a 62-year-old woman who had a sudden reduction of vision in her right eye to 20/2,000. Her fundus showed signs of an impending CRVO with marked macular edema. She had been taking antipsychotic drugs (quetiapine fumarate and risperidone) for about 2 years. She refused anti-VEGF therapy for her macular edema but selected systemic kallidinogenase...
May 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28922697/low-frequency-ranibizumab-versus-dexamethasone-implant-for-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#4
Bora Yuksel, Omer Karti, Ozan Celik, Suleyman Gokhan Kerci, Tuncay Kusbeci
BACKGROUND: The aim was to make a real-world comparison of the efficacy of ranibizumab, dexamethasone and grid laser treatments in macular oedema due to branch retinal vein occlusion (BRVO). METHODS: Forty-four eyes of 44 consecutive patients with macular oedema secondary to BRVO were included. Treatment arms comprised standard care (StCARE, n = 15), intravitreal ranibizumab (RNB, n = 14) and dexamethasone implant (DEX, n = 15). No rescue laser was performed in DEX and RNB groups...
September 18, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28916115/-retinal-vein-occlusions
#5
REVIEW
A Pierru, J-F Girmens, E Héron, M Paques
Retinal venous occlusions comprise central retinal vein occlusion, hemiretinal vein occlusions, and branch retinal vein occlusions. They are associated with arterial hypertension and glaucoma. Retinal vein occlusions occur more frequently in males, at a median age of 55. The pathogenesis of retinal venous occlusions remains obscure. The clinical presentation of the disease is variable. In most cases, there is a unilateral visual loss over days with a painless, white and quiet eye. However, retinal venous occlusions may also present as an abrupt and profound loss of vision, or be asymptomatic...
September 12, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28913517/intravitreal-injection-of-ziv-aflibercept-in-the-treatment-of-choroidal-and-retinal-vascular-diseases
#6
Kamran HodjatJalali, Shiva Mehravaran, Hooshang Faghihi, Hassan Hashemi, Pegah Kazemi, Hadith Rastad
PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention...
September 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28911993/ocular-manifestations-of-familial-transthyretin-amyloidosis
#7
Margaret M Reynolds, Kevin K Veverka, Morie A Gertz, Angela Dispenzieri, Steven R Zeldenrust, Nelson Leung, Jose S Pulido
PURPOSE: Among patients with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type. Patients with TTR amyloidosis have been noted to have ocular, especially vitreous, involvement. In this report, an analysis of the types and frequency of ocular manifestations in TTR amyloidosis is presented. DESIGN: Observational case series. METHODS: Two hundred and sixty-three patients who presented to Mayo Clinic with TTR amyloidosis between January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis database maintained by the Department of Hematology...
September 11, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28902097/retinal-microvasculature-and-visual-acuity-after-intravitreal-aflibercept-in-eyes-with-central-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#8
Andrew Winegarner, Taku Wakabayashi, Chikako Hara-Ueno, Tatsuhiko Sato, Caleb Busch, Yoko Fukushima, Kaori Sayanagi, Kentaro Nishida, Hirokazu Sakaguchi, Kohji Nishida
PURPOSE: To investigate vascular perfusion and foveal avascular zone area in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) after intravitreal aflibercept therapy in central retinal vein occlusion eyes and their association with best-corrected visual acuity. METHODS: Thirty-five subjects with central retinal vein occlusion and macular edema were evaluated. After macular edema resolution following intravitreal aflibercept, subjects underwent optical coherence tomography angiography to measure SCP and DCP perfusion and the foveal avascular zone within a 3 × 3-mm area...
September 7, 2017: Retina
https://www.readbyqxmd.com/read/28898259/association-between-retinal-vein-occlusion-and-an-increased-risk-of-acute-myocardial-infarction-a-nationwide-population-based-follow-up-study
#9
Yu-Yen Chen, Shwu-Jiuan Sheu, Hsiao-Yun Hu, Dachen Chu, Pesus Chou
OBJECTIVE: To investigate a possible association between retinal vein occlusion (RVO) and an increased risk of developing acute myocardial infarction (AMI). DESIGN: A population-based retrospective cohort study using the entire population of the Taiwan National Health Insurance Research Database (NHIRD) from 1st January, 2001 to 31st December, 2013. METHODS: A total of 37921 subjects with RVO were enrolled in the RVO group, and 113763 subjects without RVO were enrolled in the comparison group...
2017: PloS One
https://www.readbyqxmd.com/read/28883712/integrated-results-from-the-copernicus-and-galileo-studies
#10
Amelie Pielen, W Lloyd Clark, David S Boyer, Yuichiro Ogura, Frank G Holz, Jean-Francois Korobelnik, Brigitte Stemper, Friedrich Asmus, Kay D Rittenhouse, Christiane Ahlers, Robert Vitti, Namrata Saroj, Oliver Zeitz, Julia A Haller
OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO. PATIENTS AND METHODS: Patients were randomized to receive intravitreal aflibercept 2 mg every 4 weeks or sham injections until week 24. From week 24 to week 52, all intravitreal aflibercept-treated patients in both studies and sham-treated patients in COPERNICUS were eligible to receive intravitreal aflibercept based on prespecified criteria...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28865424/prevalence-pattern-and-risk-factors-of-retinal-vein-occlusion-in-an-elderly-population-in-nepal-the-bhaktapur-retina-study
#11
Raba Thapa, Sanyam Bajimaya, Govinda Paudyal, Shankar Khanal, Stevie Tan, Suman S Thapa, Ger van Rens
BACKGROUND: This study aims to explore the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of Nepal. METHOD: One thousand eight hundred sixty subjects of age 60 years and above were enrolled in a population-based, cross-sectional study. Detailed history, visual acuity, anterior segment and posterior segment examinations were done. Blood pressure, non-fasting blood sugar, body mass index and abdominal girth were measured...
September 2, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28860707/widening-use-of-dexamethasone-implant-for-the-treatment-of-macular-edema
#12
REVIEW
Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine-Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats' disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28856036/optical-coherence-tomography-angiography-of-retinal-vascular-occlusions-produced-by-imaging-guided-laser-photocoagulation
#13
Brian T Soetikno, Xiao Shu, Qi Liu, Wenzhong Liu, Siyu Chen, Lisa Beckmann, Amani A Fawzi, Hao F Zhang
Retinal vascular occlusive diseases represent a major form of vision loss worldwide. Rodent models of these diseases have traditionally relied upon a slit-lamp biomicroscope to help visualize the fundus and subsequently aid delivery of high-power laser shots to a target vessel. Here we describe a multimodal imaging system that can produce, image, and monitor retinal vascular occlusions in rodents. The system combines a spectral-domain optical coherence tomography system for cross-sectional structural imaging and three-dimensional angiography, and a fluorescence scanning laser ophthalmoscope for Rose Bengal monitoring and high-power laser delivery to a target vessel...
August 1, 2017: Biomedical Optics Express
https://www.readbyqxmd.com/read/28853639/acute-vision-loss-in-systemic-lupus-erythematosus-bilateral-combined-retinal-artery-and-vein-occlusion-as-a-catastrophic-form-of-clinical-flare
#14
M Akhlaghi, B Abtahi-Naeini, M Pourazizi
Presentation of a combination of branch retinal artery occlusion (BRAO)/central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) in systemic lupus erythematosus (SLE) is extremely rare. Herein, we have presented the case of a 29-year-old female with SLE, who simultaneously developed bilateral CRVO and BRAO/CRAO in the absence of antiphospholipid syndrome (APS) as a catastrophic form of clinical flare. A combinatorial diagnosis of CRVO and BRAO/CRAO should be considered during clinical flare-up in a patient with SLE who presents with rapidly progressive visual loss...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28837729/analyzing-and-predicting-visual-acuity-outcomes-of-anti-vegf-therapy-by-a-longitudinal-mixed-effects-model-of-imaging-and-clinical-data
#15
Wolf-Dieter Vogl, Sebastian M Waldstein, Bianca S Gerendas, Thomas Schlegl, Georg Langs, Ursula Schmidt-Erfurth
Purpose: We develop a longitudinal statistical model describing best-corrected visual acuity (BCVA) changes in anti-VEGF therapy in relation to imaging data, and predict the future BCVA outcome for individual patients by combining population-wide trends and initial subject-specific time points. Methods: Automatic segmentation algorithms were used to measure intraretinal (IRF) and subretinal (SRF) fluid volume on monthly spectral-domain optical coherence tomography scans of eyes with central retinal vein occlusion (CRVO) receiving standardized anti-VEGF treatment...
August 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28828184/switch-of-intravitreal-therapy-for-macular-edema-secondary-to-retinal-vein-occlusion-from-anti-vegf-to-dexamethasone-implant-and-vice-versa
#16
Amelie Pielen, Anima Desiree Bühler, Sonja Ute Heinzelmann, Daniel Böhringer, Thomas Ness, Bernd Junker
PURPOSE: To evaluate the anatomical and functional outcome of intravitreal dexamethasone implant for macular edema secondary to central (C) or branch (B) retinal vein occlusion (RVO) in patients with persistent macular edema (ME) refractory to intravitreal antivascular endothelial growth factor (VEGF) treatment compared to treatment naïve patients and to dexamethasone-refractory eyes switched to anti-VEGF. METHODS: Retrospective, observational study including 30 eyes previously treated with anti-VEGF (8 CRVO, 22 BRVO, mean age 69 ± 10 yrs), compared to 11 treatment naïve eyes (6 CRVO, 5 BRVO, 73 ± 11 yrs) and compared to dexamethasone nonresponders (2 CRVO, 4 BRVO, 69 ± 12)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28811936/real-life-management-of-patients-with-retinal-vein-occlusion-using-i-macula-web-platform
#17
Massimo Nicolò, Monica Bonetto, Raffaella Rosa, Donatella Musetti, Maria Musolino, Carlo Enrico Traverso, Mauro Giacomini
AIM: Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. MATERIAL AND METHODS: A retrospective, observational study using the I-Macula Web platform. RESULTS: Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p = 0.0235) and central macular thickness (p < 0...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28810002/retinal-oximetry-discovers-novel-biomarkers-in-retinal-and-brain-diseases
#18
REVIEW
Einar Stefánsson, Olof Birna Olafsdottir, Anna Bryndis Einarsdottir, Thorunn Scheving Eliasdottir, Thor Eysteinsson, Wouter Vehmeijer, Evelien Vandewalle, Toke Bek, Sveinn Hakon Hardarson
Purpose: Biomarkers for several eye and brain diseases are reviewed, where retinal oximetry may help confirm diagnosis or measure severity of disease. These include diabetic retinopathy, central retinal vein occlusion (CRVO), retinitis pigmentosa, glaucoma, and Alzheimer's disease. Methods: Retinal oximetry is based on spectrophotometric fundus imaging and measures oxygen saturation in retinal arterioles and venules in a noninvasive, quick, safe manner. Retinal oximetry detects changes in oxygen metabolism, including those that result from ischemia or atrophy...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28807635/sustained-benefits-of-ranibizumab-with-or-without-laser-in-branch-retinal-vein-occlusion-24-month-results-of-the-brighter-study
#19
Ramin Tadayoni, Sebastian M Waldstein, Francesco Boscia, Heinrich Gerding, Margarita Gekkieva, Elizabeth Barnes, Ayan Das Gupta, Andreas Wenzel, Ian Pearce
PURPOSE: To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized visual acuity (VA) stabilization criteria in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). DESIGN: Phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study. PARTICIPANTS: A total of 455 patients. METHODS: Patients were randomized (2:2:1) to ranibizumab 0...
August 11, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28803326/short-term-results-of-endovascular-surgery-with-tissue-plasminogen-activator-injection-for-central-retinal-vein-occlusion
#20
Masaaki Ishida, Shinya Abe, Takuya Nakagawa, Atsushi Hayashi
PURPOSE: To examine the effects of retinal endovascular surgery (REVS) with tissue plasminogen activator injection into the retinal vein in central retinal vein occlusion (CRVO) eyes. METHODS: Sixteen consecutive CRVO patients with macular edema and decreased visual acuity who were referred to Toyama University Hospital between March 2014 and February 2016 were included in this study. Changes in visual acuity (VA) and central retinal thickness (CRT) were evaluated up to 6 months after REVS...
August 12, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
keyword
keyword
53072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"